FDA Clearance Tracker · P100034-S013
OPTUNE (FORMERLY THE NOVOTTF-100A SYSTEM)
Last checked: Nov 20, 2026Latest source record: Oct 5, 2015 (this decision)Source: openFDAMethods & limitations
Decided
Oct 5, 2015
Approved
Time to decision
178 days
Received Apr 10, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P100034-S013
- Device name
- OPTUNE (FORMERLY THE NOVOTTF-100A SYSTEM)
- Applicant
- Novocure, GmbH
- Applicant location
- Baar
- Received
- Apr 10, 2015
- Decided
- Oct 5, 2015
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P100034
Device type
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE OPTUNE (FORMERLY THE NOVOTTF-100A SYSTEM). THIS DEVICE IS INDICATED AS A TREATMENT FOR ADULT PATIENTS (22 YEARS OF AGE OR OLDER) WITH HISTOLOGICALLY-CONFIRMED GLIOBLASTOMA MULTIFORME (GBM). OPTUNE WITH TEMOZOLOMIDE IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED, SUPRATENTORIAL GLIOBLASTOMA FOLLOWING MAXIMAL DEBULKING SURGERY AND COMPLETION OF RADIATION THERAPY TOGETHER WITH CONCOMITANT STANDARD OF CARE CHEMOTHERAPY. OPTUNE WAS PREVIOUSLY APPROVED IN 2011 FOR THE TREATMENT OF RECURRENT GBM WITH THE FOLLOWING INDICATIONS FOR USE (IFU): OPTUNE IS INDICATED FOLLOWING HISTOLOGICALLY-OR RADIOLOGICALLY-CONFIRMED RECURRENCE IN THE SUPRA-TENTORIAL REGION OF THE BRAIN AFTER RECEIVING CHEMOTHERAPY. THE DEVICE IS INTENDED TO BE USED AS A MONOTHERAPY, AND IS INTENDED AS AN ALTERNATIVE TO STANDARD MEDICAL THERAPY FOR GBM AFTER SURGICAL AND RADIATION OPTIONS HAVE BEEN EXHAUSTED.
Source documents
Other decisions for Novocure, GmbH
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Optune PaxBreakthroughPMA
P250034 · Decided Feb 11, 2026 · 180 days after receipt
Device type: Low Electric Field Generator for Pancreatic Cancer Treatment (SHC) · General & Plastic Surgery
- Optune LuaPMA
P230042 · Decided Oct 15, 2024 · 305 days after receipt
Device type: Electrical tumor treatment fields for non-small cell lung cancer (SDA) · Anesthesiology & Respiratory
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.